Chapter
| Ref.
| Authors
| Title
| Year
|
Vectorization
| [1]
| Couvreur P.
| L'encapsulation de médicament
| 2003
|
Vectorization
| [2]
| Andrieux K. and al.
| Nanotechnology and new drug
| 2003
|
Vectorization
| [3]
| Torchilin V.P.
| Recent Approaches to Intracellular Delivery of Drugs and DNA and Organelle Targeting
| 2006
|
Vectorization
| [4]
| Davis M.E. and al.
| Nanoparticle therapeutics: an emerging treatment modality for cancer
| 2008
|
Vectorization
| [5]
| Seow Y. and al.
| Biological Gene Delivery Vehicles: Beyond Viral Vectors
| 2009
|
Vectorization
| [6]
| Decroly E.
| Vectorology
| 2005
|
Vectorization
| [7]
| Robbins P.D. and al.
| Viral Vectors for Gene Therapy
| 1998
|
Vectorization
| [8]
| Wei M.Q. and al.
| Bacterial targeted tumour therapy-dawn of a new era
| 2008
|
Vectorization
| [9]
| Ryan R.M. and al.
| Use of bacteria in anti-cancer therapies
| 2005
|
Vectorization
| [10]
| Mehnert
| Solid lipid nanoparticles: Production, characterization and applications
| 2001
|
Vectorization
| [11]
| Lasic D.D.
| Liposomes in gene therapy
| 1996
|
Vectorization
| [12]
| Lutten J. and al.
| Biodegradable polymers as non-viral carriers for plasmid DNA delivery
| 2008
|
Vectorization
| [13]
| Jiskoot W. and al.
| Immunological Risk of Injectable Drug Delivery Systems
| 2009
|
Vectorization
| [14]
| Head M. and al.
| Mechanism and computer simulation of immune complex formation, opsonization, and clearance
| 1996
|
Vectorization
| [15]
| Koide H. and al.
| Particle size-dependent triggering of accelerated blood clearance phenomenon
| 2008
|
Vectorization
| [16]
| Ishida T. and al.
| Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes
| 2005
|
Vectorization
| [17]
| Wang XY and al.
| Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes
| 2007
|
Vectorization
| [18]
| Tosi M.F. and al.
| Innate immune responses to infection
| 2005
|
Vectorization
| [19]
| Linkov I and al.
| Nanotoxicology and nanomedicine: making hard decisions
| 2008
|
Chapter
| Ref.
| Authors
| Title
| Year
|
Tissue Vector
| [1]
| Ronald S. and al.
| Antimicrobial mechanisms of phagocytes and bacterial evasion strategies
| 2009
|
Tissue Vector
| [2]
| Clark B. Inderlied and al.
| The Mycobacterium avium Complex
| 1993
|
Tissue Vector
| [3]
| Nisheeth Agarwal and al.
| Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase
| 2009
|
Tissue Vector
| [4]
| Hunter R.L. and al.
| Pathology of postprimary tuberculosis in humans and mice: contradiction of long-held beliefs
| 2007
|
Tissue Vector
| [5]
| Axelrod S and al.
| Delay of phagosome maturation by a mycobacterial lipid is reversed by nitric oxide
| 2008
|
Tissue Vector
| [6]
| Nicole N van der Wel and al.
| Subcellular localization of mycobacteria in tissues and detection of lipid antigens in organelles using cryo-techniques for light and electron microscopy
| 2005
|
Tissue Vector
| [7]
| Claudia Nobrega and al.
| The thymus as a target for mycobacterial infections
| 2007
|
Chapter
| Ref.
| Authors
| Title
| Year
|
Cell Vector
| [1]
| Harrison Echols and al.
| Genetic Map of Bacteriophage Lambda
| 1978
|
Cell Vector
| [2]
| Joseph Sambrook and al.
| Molecular Cloning: A Laboratory Manual (Third Edition)
| 2001
|
Cell Vector
| [3]
| Court DL and al.
| A New Look at Bacteriophage lambda Genetic Networks
| 2007
|
Cell Vector
| [4]
| Ortega ME and al.
| Bacteriophage Lambda gpNu1 and Escherichia coli IHF Proteins Cooperatively Bind and Bend Viral DNA: Implications for the Assembly of a Genome-Packaging Motor
| 2006
|
Cell Vector
| [5]
| Feiss M. and al.
| Bactériophage Lambda Terminase and the Mechanism of Viral DNA Packaging
| 2005
|
Cell Vector
| [6]
| Hang JQ and al.
| The Functional Asymmetry of cosN, the Nicking Site for Bacteriophage λ DNA Packaging, Is Dependent on the Terminase Binding Site, cosB
| 2001
|
Cell Vector
| [7]
| Becker A and al.
| Bacteriophage lambda DNA : The begginning of the End
| 1990
|
Cell Vector
| [8]
| Hochschild A and al.
| The bactériophage lambda cI protein finds an asymmetric solution
| 2009
|
Cell Vector
| [9]
| Phoebe L.Stewart1 and al.
| Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization
| 1997
|
Chapter
| Ref.
| Authors
| Title
| Year
|
Therapeutic Plasmide
| [1]
| Ortega ME et al.
| Bacteriophage lambda gpNu1 and Escherichia coli IHF proteins cooperatively bind and bend viral DNA: implications for the assembly of a genome-packaging motor
| 2006
|
Therapeutic Plasmide
| [2]
| Joseph Sambrook and al.
| Molecular Cloning: A Laboratory Manual (Third Edition)
| 2001
|
Therapeutic Plasmide
| [3]
| Court DL and al.
| A New Look at Bacteriophage lambda Genetic Networks
| 2007
|
Therapeutic Plasmide
| [4]
| Feiss M. and al.
| Viral Genome Packaging Machines: Genetics, Structure and Mechanism
| 2005
|
Therapeutic Plasmide
| [5]
| Hang JQ and al.
| The Functional Asymmetry of cosN, the Nicking Site for Bacteriophage λ DNA Packaging, Is Dependent on the Terminase Binding Site, cosB
| 2001
|
Therapeutic Plasmide
| [6]
| Becker A and al.
| Bacteriophage lambda DNA : The begginning of the End
| 1990
|
Therapeutic Plasmide
| [7]
| Young et al.
| Effect of a DNA nuclear targeting sequence on gene transfer and expression of plasmids in the intact vasculature
| 2003
|
Chapitre
| Ref.
| Auteurs
| Titre
| Année
|
Antitumor action
| [1]
| Chunlin Yang et al
| Adenovirus-mediated Wild-Type p53 Expression Induces Apoptosis and Suppresses Tumorigenesis of Prostatic Tumor Cells
| 1995
|
Antitumor action
| [2]
| Corrado Cirielli et al.
| Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma
| 1999
|
Antitumor action
| [3]
| Su-Ping Ren et al.
| Adenoviral-mediated transfer of human wild-type p53, GM-CSF and B7-1 genes results in growth suppression and autologous anti-tumor cytotoxicity of multiple myeloma cells in vitro
| 2006
|
Antitumor action
| [4]
| Zhao-hua Qiu et al
| Growth suppression and immunogenicity enhancement of Hep-2 or primary laryngeal cancer cells by adenovirus-mediated co-transfer of human wild-type p53, granulocyte-macrophage colony-stimulating factor and B7-1 genes
| 2002
|
Antitumor action
| [5]
| Zhao-hua Qiu et al.
| Co-transfer of human wild-type p53 and granulocyte-macrophage colony-stimulating factor genes via recombinant adenovirus induces apoptosis and enhances immunogenicity in laryngeal cancer cells
| 2001
|
Antitumor action
| [6]
| Markus Reiser et al.
| Induction of cell proliferation arrest and apoptosis in hepatoma cells through adenoviral-mediated transfer of p53 gene
| 2000
|
Antitumor action
| [7]
| Louis L. Pisters et al.
| Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer
| 2004
|
Antitumor action
| [8]
| Susan C. Modesitt et al.
| In Vitro and in Vivo Adenovirus-mediated p53 and p16 Tumor Suppressor Therapy in Ovarian Cancer
| 2001
|
Antitumor action
| [9]
| Yong-song GUAN et al.
| Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up
| 2009
|
Chapter
| Ref.
| Authors
| Title
| Year
|
Ethics
| [1]
| Joël Rosnay
| Biologie de synthèse: Enjeux et défis pour l’humanité
| 2004
|
Ethics
| [2]
| Synbiosafe
| http://www.synbiosafe.eu/forum/
| 2008
|
Ethics
| [3]
| Bernadette Bensaude Vincent, Dorothée Benoit-Browaeys
| Petite typologie de la biologie synthétique et enjeux éthiques
| 2009
|
Ethics
| [4]
| Anna Deplazes Æ Markus Huppenbauer
| Synthetic organisms and living machines
| 2004
|
Ethics
| [5]
| Schmidt M, Ganguli-Mitra A,and al.
| A priority paper for the societal and ethical aspects of synthetic biology
| 2009
|
Ethics
| [6]
| Parens E, Johnston J, Moses J.
| Ethics. Do we need "synthetic bioethics"?
| 2009
|